Neotropix believes that it’s leading candidate, NTX-010, will be effective in producing survival benefit in patients with cancers possessing neuroendocrine features, such as small cell lung cancer. In addition to pursuing its lead product for SCLC, the Company will seek to create a pipeline
of therapeutic candidates and to develop a product franchise. The goal will be to have a new IND filed every 18-24 months so that at the time of NTX-010 approval there are multiple drugs in the clinic focused on solid tumor cancers.

Neotropix has identified numerous sources of previously uncharacterized viruses that, until now, have not been tested for key oncolytic properties. The Company will continue to add to its pipeline by screening these unique untapped resources with its proprietary ViruScreen process. Because the ViruScreen process is maintained as a trade secret the Company does not disclose its process used to identify viruses that would be good drug candidates. Recent screens resulted in the identification of 19 research candidates that replicate in one or more cancer indications and that are likely to have other key factors for commercial success. Neotropix believes that viruses such as these are a rich source of potential therapeutics and associated technologies.